Search PubMed⌕ Search

Biomedical subjects

G Kakuk

Publications and source records attributed to G Kakuk.

At least 55 records · Page 3Linked to original sources
PubMed1988

Experience with brulamycin therapy in dialysed patients.

Forty-two patients with chronic renal insufficiency were subjected to Brulamycin therapy to combat complications such as sepsis, infection of the lower respiratory tract (bronchopneumonia) or of the urinary tract, Cimino fistula inflammation or peritonitis when the pathogenic agent was sensitive to nothing but aminoglycosides. The proper Brulamycin dose was selected under close clinical and laboratory control so as to fit the dialysed patient and his state of impaired renal function. The various forms of dialysis have been studied to determine their Brulamycin blood level diminishing effects. Familiarity with these effects is as important as with the patient's age, sex, body weight and actual state of renal function. The results confirm the experience gained by other authors that Brulamycin treatment--in curative non-toxic doses as indicated by the blood level index--is useful against severe infectious complications in anuric patients.

Adolescent↗
PubMed1980

Goodpasture's syndrome: haemodialysis, pacing and extrapulmonary oxygenation.

Two cases of Goodpasture's syndrome are reported. Intensive therapy, extracorporeal oxygenation by haemodialysis, assisted respiration and short-term pacing were applied together with immunosuppressive treatment and repeated exchange transfusions. By this treatment combined with bilateral nephrectomy a few weeks' remission was attained in a young female patient. An intensive therapy of this kind is recommended in rapid progressive glomerulonephritis of other types as well.

Adult↗
PubMed1979

[Examination of lymphokines in patients with hemodialysis (author's transl)].

The activity of LIF after Con A stimulation was examined in patients with hemodialysis and chronic uremia. It was found that LIF activity is reduced in uremia compared with healthy controls. The absolute number of T lymphocytes was reduced as well as the number of active E rosettes. An inhibitory effect was found in vitro by isolated middle molecules from uremic serum and ultrafiltrate. The LIF production of normal lymphocytes and the number of active rosettes are significantly reduced by substances isolated from serum and ultrafiltrate with molecular weight of 1 000 to 1 500 Dalton. The authors think that these uremic middle molecules are responsible for the already known reducing of immune response by uremia. The uremic substances are dialysable.

Adult↗
PubMed1977

[Nephropathy associated with systemic lupus erythematosus].

The investigation of needle- kidney biopsy from patients with SLE- nephrotic syndrome was carried out by the aid of light- immunofluorescent- and electron microscopy. Membranous-, focal-proliferative-, and diffuse-proliferative forms of the SLE- nephrotic syndrome were distinguished. Clinical characteristics of the different forms are described. Authors believe, that the underlying process of nephrological symptoms of various degree as well as readily distinguishable clinico-pathological pictures is the formation of circulating immunocomplexes of different size, developing due to basic disease itself. Comparison of the clinical symptoms and the morphological picture indicate that the elapse of time between the onset of the underlying disease and the nephrotic syndrome has an important part in the formation of the SLE-nephropathy of focal- and diffuse-proliferative type.

Adolescent↗
PubMed1977

[The action spectrum of cytostatics in the management of glomerulonephritis].

It was reported on the results of the cytostatic immunosuppressive treatment during a 6 years' observation time in 100 patients with glomerulonephritis in immunopathogenesis. The diagnosing was made according to the homogeneous opinion: clinical, immunological and histological. Of the 100 patients 33 suffered from SLE and 67 from other nephropathies with immunopathogenesis. In the therapy were used prednisolone, 6-mercaptopurine, azathioprine, cyclophosphamide and their combination, respectively. On the one hand, the therapeutic results were estimated as short-term results, on the other hand as long-term results with regard to the clinical syndromes as well as to the individual histological forms according to the categories of the full remission, the partial remission and also as "unchanged". It was established, whether an optimum result may be achieved in the different clinical and histological types. The best results may be achieved with the combination of 6-mercaptopurine and cyclophosphamide. The cytostatic therapy of the glomerulopathies should be used more aimedly in different clinical syndromes and histological forms.

Antineoplastic Agents↗